Advances in analytical technologies help drive progress in the development and manufacturing of biopharmaceutical products. Improved analytical technologies enable better identification of relevant critical quality attributes, help assure product quality, advance non clinical studies, identify biomarkers/diagnostics, and increase general knowledge of products and processes.
This IABS Meeting will bring together scientists from academia, industry, government, and other organizations for in-depth exploration of the latest cuttingedge advances in analytical technologies for developing biopharmaceutical products ranging from monoclonal antibody therapeutics to new modalities such as viral vector mediated gene therapies and vaccines, mRNA vaccines, and adoptive cell therapies.
Tentative sessions include:
Analytical technologies for novel modalities such as cell and gene therapies and mRNA products;
Analytical technologies for monitoring process and product quality;
New tools for bioassays and immunogenicity assays;
Novel standards for advancing analytical technologies; and
Next generation analytical technologies utilizing AI, supporting non-clinical studies, and biomarker/diagnostic development.
Scientific Committee
Mark Schenerman, University of Maryland, Co-Chair
Shawn Novick, IABS Chair
Michael Tarlov, NIST, Co-Chair
Christopher Bravery, IABS
Michael Brenowitz, Albert Einstein College of Medicine
